Skip to main content

Endocrine Pathology

Ausgabe 3/2018

Inhalt (13 Artikel)

LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases

Maria José Carregosa Pinheiro dos Santos, André Uchimura Bastos, Vitor Rodrigues da Costa, Rosana Delcelo, Susan Chow Lindsey, Gabriel Avelar Colozza-Gama, Hongzhuang Peng, Frank J. Rauscher III, Gisele Oler, Janete Maria Cerutti

Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20

Sounak Gupta, Divya Sahu, John S. Bomalaski, Igor Frank, Stephen A. Boorjian, Prabin Thapa, John C. Cheville, Donna E. Hansel

Clinical Impact of p27Kip1 and CaSR Expression on Primary Hyperparathyroidism

Gozde Sengul Aycicek, Berna Imge Aydogan, Mustafa Sahin, Cevriye Cansız Ersoz, Serpil Dizbay Sak, Nilgun Baskal

Open Access

Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations

George Papaxoinis, Angela Lamarca, Anne Marie Quinn, Wasat Mansoor, Daisuke Nonaka

The Value of Negative Diagnosis in Thyroid Fine-Needle Aspiration: a Retrospective Study with Histologic Follow-Up

Rita Abi-Raad, Manju Prasad, Rebecca Baldassari, Kevin Schofield, Glenda G. Callender, David Chhieng, Adebowale J. Adeniran

A Case of Gastric Neuroendocrine Neoplasm with Mixed Grade: a Distinct Type of “High”-grade Well-Differentiated Neuroendocrine Neoplasm

Elia Guadagno, Gaetano Luglio, Alessandro Iacobelli, Giorgio Borrelli, Antonio Castaldi, Gaetano De Rosa, Marialaura Del Basso De Caro

IgG4-Associated Adrenalitis—a Case Report

Wolfgang Saeger, Bernd Lohe, Christina Luise Engels, Ulrike Werner

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Molekularpathologische Untersuchungen im Wandel der Zeit

11.04.2024 | Pathologie | Schwerpunkt: Next Generation Pathology

Vergleichende Pathologie in der onkologischen Forschung

Open Access 08.04.2024 | GIST | CME

Gastrointestinale Stromatumoren

Wo stehen wir?

03.04.2024 | Zielgerichtete Therapie | Schwerpunkt: Next Generation Pathology

Personalisierte Medizin in der Onkologie